参考文献/References:
[1] Ibanez B,James S,Agewall S,et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J].Eur Heart J,2018,39(2):119-177.
[2] Li J,Li X,Wang Q,et al.ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data[J].Lancet,2015,385(9966):441-451.
[3] Soar J,Maconochie I,Wyckoff MH,et al.2019 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations: summary from the basic life support; advanced life support; pediatric life support; neonatal life support; education,implementation,and teams; and first aid task forces[J].Circulation,2019,140(24):e826-e880.
[4] Sondergaard KB,Wissenberg M,Gerds TA,et al.Bystander cardiopulmonary resuscitation and long-term outcomes in out-of-hospital cardiac arrest according to location of arrest[J].Eur Heart J,2019,40(3):309-318.
[5] Dumas F,Bougouin W,Geri G,et al.Emergency percutaneous coronary intervention in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT Ⅱ registry[J].JACC Cardiovasc Interv,2016,9(10):1011-1018.
[6] Kudenchuk PJ,Cobb LA,Copass MK,et al.Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation[J].N Engl J Med,1999,341(12):871-878.
[7] Nademanee K,Taylor R,Bailey WE,et al.Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy[J].Circulation,2000,102(7):742-747.
[8] Brodine WN,Tung RT,Lee JK,et al.Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II)[J].Am J Cardiol,2005,96(5):691-695.
[9] Vaughan Williams EM.A classification of antiarrhythmic actions reassessed after a decade of new drugs[J].J Clin Pharmacol,1984,24(4):129-147.
[10] Epstein AE,Hallstrom AP,Rogers WJ,et al.Mortality following ventricular arrhythmia suppression by encainide,flecainide,and moricizine after myocardial infarction.The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST)[J].JAMA,1993,270(20):2451-2455.
[11] Cardiac Arrhythmia Suppression Trial Ⅲ.Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction[J].N Engl J Med,1992,327(4):227-233.
[12] Ellison KE,Hafley GE,Hickey K,et al.Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT)[J].Circulation,2002,106(21):2694-2699.
[13] A randomized trial of propranolol in patients with acute myocardial infarction.I.Mortality results[J].JAMA,1982,247(12):1707-1714.
[14] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会.2020室性心律失常中国专家共识(2016共识升级版)[J].中国心脏起搏与心电生理杂志,2020,34(3):189-253.
[15] Burkart F,Pfisterer M,Kiowski W,et al.Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)[J].J Am Coll Cardiol,1990,16(7):1711-1718.
[16] Cairns JA,Connolly SJ,Roberts R,et al.Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT.Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators[J].Lancet,1997,349(9053):675-682.
[17] Julian DG,Camm AJ,Frangin G,et al.Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT.European Myocardial Infarct Amiodarone Trial Investigators[J].Lancet,1997,349(9053):667-674.
[18] Bardy GH,Lee KL,Mark DB,et al.Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure[J].N Engl J Med,2005,352(3):225-237.
[19] Waldo AL,Camm AJ,deRuyter H,et al.Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction.The SWORD Investigators.Survival With Oral d-Sotalol[J].Lancet,1996,348(9019):7-12.
[20] Kehr J,Binfield A,Maxwell F,et al.Fascicular tachycardia in infancy and the use of verapamil: a case series and literature review[J].Arch Dis Child,2019,104(8):789-792.
[21] Kafka H,Langevin L,Armstrong PW.Serum magnesium and potassium in acute myocardial infarction.Influence on ventricular arrhythmias[J].Arch Intern Med,1987,147(3):465-469.
[22] Cooper HA,Dries DL,Davis CE,et al.Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction[J].Circulation,1999,100(12):1311-1315.
[23] Packer M.What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?[J].Eur Heart J,2020,41(18):1757-1763.
[24] Moss AJ,Hall WJ,Cannom DS,et al.Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.Multicenter Automatic Defibrillator Implantation Trial Investigators[J].N Engl J Med,1996,335(26):1933-1940.
[25] Buxton AE,Lee KL,Fisher JD,et al.A randomized study of the prevention of sudden death in patients with coronary artery disease.Multicenter Unsustained Tachycardia Trial Investigators[J].N Engl J Med,1999,341(25):1882-1890.
[26] Zhang S,Ching CK,Huang D,et al.Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: Improve SCA clinical trial[J].Heart Rhythm,2020,17(3):468-475.
[27] Al-Khatib SM,Stevenson WG,Ackerman MJ,et al.2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice Guidelines and the Heart Rhythm Society[J].Circulation,2018,138(13):e272-e391.
[28] Komatsu Y,Hocini M,Nogami A,et al.Catheter ablation of refractory ventricular fibrillation storm after myocardial infarction[J].Circulation,2019,139(20):2315-2325.
[29] Markman TM,Nazarian S.Treatment of ventricular arrhythmias:What’s New?[J].Trends Cardiovasc Med,2019,29(5):249-261.
[30] Izquierdo M,Sanchez-Gomez JM,Ferrero de Loma-Osorio A,et al.Endo-epicardial versus only-endocardial ablation as a first line strategy for the treatment of ventricular tachycardia in patients with ischemic heart disease[J].Circ Arrhythm Electrophysiol,2015,8(4):882-889.
[31] Sun H,Nasi-Er BG,Wang X,et al.Tragus nerve stimulation suppresses post-infarction ventricular arrhythmia by modulating autonomic activity and heterogeneities of cardiac receptor distribution[J].Med Sci Monit,2020,26:e922277.
[32] Zhai Z,Zhao S,Tang M,et al.Chronic median nerve modulation reduces ventricular arrhythmia and improves ventricular function in a postmyocardial infarction rabbit model[J].Cardiovasc Ther,2018,36(4):e12437.
[33] Zhang WH,Zhou QN,Lu YM,et al.Renal denervation reduced ventricular arrhythmia after myocardial infarction by inhibiting sympathetic activity and remodeling[J].J Am Heart Assoc,2018,7(20):e009938.
[34] Jackson N,Gizurarson S,Azam MA,et al.Effects of renal artery denervation on ventricular arrhythmias in a postinfarct model[J].Circ Cardiovasc Interv,2017,10(3):e004172.
[35] Zhou M,Liu Y,Xiong L,et al.Cardiac sympathetic afferent denervation protects against ventricular arrhythmias by modulating cardiac sympathetic nerve activity during acute myocardial infarction[J].Med Sci Monit,2019,25:1984-1993.
[36] Sasano T,McDonald AD,Kikuchi K,et al.Molecular ablation of ventricular tachycardia after myocardial infarction[J].Nat Med,2006,12(11):1256-1258.
[37] Greener ID,Sasano T,Wan X,et al.Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction[J].J Am Coll Cardiol,2012,60(12):1103-1110.
[38] Prunier F,Kawase Y,Gianni D,et al.Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion [J].Circulation,2008,118(6):614-624.
[39] Hare JM,Fishman JE,Gerstenblith G,et al.Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial[J].JAMA,2012,308(22):2369-2379.
[40] Liu YW,Chen B,Yang X,et al.Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates[J].Nat Biotechnol,2018,36(7):597-605.
[41] Jeyaraman MM,Rabbani R,Copstein L,et al.Autologous bone marrow stem cell therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis[J].Can J Cardiol,2017,33(12):1611-1623.
[42] Cuculich PS,Schill MR,Kashani R,et al.Noninvasive cardiac radiation for ablation of ventricular tachycardia[J].N Engl J Med,2017,377(24):2325-2336.
[43] Lehmann HI,Graeff C,Simoniello P,et al.Feasibility study on cardiac arrhythmia ablation using high-energy heavy ion beams[J].Sci Rep,2016,6:38895.
[44] Robinson CG,Samson PP,Moore KMS,et al.Phase Ⅰ/Ⅱ trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia[J].Circulation,2019,139(3):313-321.
[45] Nussinovitch U,Shinnawi R,Gepstein L.Modulation of cardiac tissue electrophysiological properties with light-sensitive proteins[J].Cardiovasc Res,2014,102(1):176-187.
[46] Nyns ECA,Kip A,Bart CI,et al.Optogenetic termination of ventricular arrhythmias in the whole heart: towards biological cardiac rhythm management[J].Eur Heart J,2017,38(27):2132-2136.
相似文献/References:
[1]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(6):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[2]张耀庭 李烽 朱永翔 陆丽洁 龙明智.沙库巴曲/缬沙坦在室性心律失常中的研究进展[J].心血管病学进展,2019,(7):982.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.004]
ZHANG Yaoting,LI Feng,ZHU Yongxiang,et al.Research Progress of Sacubitril/Valsartan in Ventricular Arrhythmia[J].Advances in Cardiovascular Diseases,2019,(6):982.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.004]
[3]孙洋.基质金属蛋白酶与心肌梗死后心脏重构[J].心血管病学进展,2019,(8):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
SUN Yang.Matrix Metalloproteinases in Cardiac Remodeling after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(6):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
[4]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(6):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[5]常文婧 王丽娜.Hippo通路在心脏发育、再生和疾病中的作用[J].心血管病学进展,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
CHANG Wenjin,WANG Lina.Role of Hippo Pathway in Heart Development,Regeneration and Disease[J].Advances in Cardiovascular Diseases,2019,(6):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
[6]王宇 周思维 张莎 吴弘.植入型心律转复除颤器在心肌梗死后心脏性猝死中的研究进展[J].心血管病学进展,2020,(1):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
WANG Yu,ZHOU Siwei,ZHANG Sha,et al.Implantable Cardioverter Defibrillator in Sudden Cardiac Death after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(6):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
[7]梁砚薷李晶洁.神经元型钠通道在室性心律失常发生机制中的作用[J].心血管病学进展,2020,(1):43.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.012]
LIANG Yanru,LI Jingjie.Role of Neuronal Sodium Channels in Development of Ventricular Arrhythmias[J].Advances in Cardiovascular Diseases,2020,(6):43.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.012]
[8]刘磊 杨震.心肌梗死后左心室壁瘤相关室性心律失常的形成机制与治疗进展[J].心血管病学进展,2020,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.013]
LIU Lei,YANG Zhen.Mechanism and Progress in Treatment of Post-infarction Left Ventricular Aneurysm with Ventricular Arrhythmias[J].Advances in Cardiovascular Diseases,2020,(6):46.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.013]
[9]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[10]王茜 李晶洁.细胞学机制在调控心肌梗死后炎症反应中的研究进展[J].心血管病学进展,2020,(2):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
WANG QianLI Jingjie.Cytological Mechanisms in Regulation of The Post-infarction Inflammatory Response[J].Advances in Cardiovascular Diseases,2020,(6):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
[11]毕莹莹 杨双 张舒红 唐艳红.P2X3R对心肌梗死大鼠交感神经重构和室性心律失常的影响[J].心血管病学进展,2023,(9):858.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.021]
Bi Yingying,Yang Shuang,Zhang Shuhong,et al.Effect of P2X3R on Sympathetic Remodeling and Ventricular Arrhythmias in Rats with Myocardial Infarction[J].Advances in Cardiovascular Diseases,2023,(6):858.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.021]